How much of the CT.gov disclosure gap sits inside industry?

Project

This page is designed as the visible front door on GitHub Pages: the dashboard, paper, protocol, and the rest of the CT.gov series are all one click from here.

Open dashboard at root Read E156 micro-paper Open protocol Open series hub

Forty-four thousand long-past missing-results records remain inside the industry bucket alone.

Industry stock, March 29, 2026 registry snapshot

A standalone E156 project on how much long-past non-disclosure and structural sparsity remain inside industry-linked ClinicalTrials.gov records.

Industry studies

128,464

All industry-linked records

Closed interventional

87,296

Industry only

2-year stock

44,007

Older studies with no results

Eligible rate

58.1%

Older closed interventional

Top sponsors

The largest unresolved industry blocks sit with GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Sanofi, and Pfizer.

Why this figure matters: the count view shows where the biggest visible backlog sits, which is a different question from which sponsor has the very worst percentage.

Read Across Projects

Across The Series

The split projects are meant to be read together: one for industry, one for sponsor classes, one for phases, and one for structural missingness.

Sponsor-Class Hiddenness

CT.gov Sponsor-Class Hiddenness

A standalone E156 project comparing sponsor classes on rate, stock, and structural sparsity rather than flattening everything into one leaderboard.

Phase Reporting Gap

CT.gov Phase Reporting Gap

A standalone E156 project on how reporting gaps change by trial phase, showing that phase structure matters alongside sponsor class.

Structural Missingness

CT.gov Structural Missingness

A standalone E156 project on the descriptive fields that disappear from ClinicalTrials.gov even before results reporting is considered.